CA-HITACHI
29.5.2024 01:01:27 CEST | Business Wire | Press release
Hitachi, Ltd. (TSE:6501), and Google Cloud today announced a multi-year partnership to accelerate enterprise innovation and productivity with generative AI. Hitachi will form a new business unit focused on helping businesses solve industry challenges with Gemini models, Vertex AI, and other cloud technologies, and it will also adopt Google Cloud’s AI to enhance its own products and services. Through the partnership, Hitachi will further accelerate growth of Lumada, its core digital business, and it will advance operational efficiencies for the Hitachi Group.
Led by GlobalLogic, a leader in digital engineering and a subsidiary of the Hitachi Group, the companies will establish the Hitachi Google Cloud Business Unit and the Google Cloud Center of Excellence (CoE) to rapidly scale Google Cloud technology to new and existing enterprise customers. Additionally, Hitachi will collaborate with Google Cloud to incorporate training on Google Cloud’s GenAI as part of Hitachi’s GenAI Professional training program. The program will deepen the expertise and managed services available through these business units, which will ensure large-scale organizations have access to the resources needed to fundamentally improve how they operate with AI.
Additional focus areas of the partnership will include:
- New GenAI solutions for software modernization and customer service: Hitachi will use Gemini models to build solutions that help businesses efficiently modernize legacy software systems, and it will adopt Google Cloud Contact Center AI to power more effective and accurate customer service experiences. For instance, using Google Cloud Agent Assist, customer service representatives can be supported with real-time knowledge assistance and resolution suggestions to help them be more productive and provide better service. The new solutions will be compatible with GlobalLogic's Platform of Platforms architecture, which is designed to address the needs of intelligent enterprises.
- Enabling safe, secure GenAI solutions for on-premises and cloud environments: Hitachi’s new solutions will support customers running both on-premises and in the cloud, enabling enterprises to modernize operations while retaining existing IT environments. The solutions will also be compatible with Virtual Storage Platform One, so that users can build GenAI applications using data stored on Hitachi Vantara’s hybrid cloud platform.
- Joint go-to-market initiatives: Hitachi and Google Cloud will better align their sales, marketing, and engineering teams to ensure that customers across industries have access to the resources needed to optimally deploy and manage GenAI projects through Hitachi Google Cloud Business Unit and Google Cloud CoE. This will include the GenAI Professionals that Hitachi trains on Google Cloud technology.
- Strengthen GenAI talent development: Hitachi’s GenAI Professionals play a critical role in supporting customers' transformation with AI, and Hitachi will train more than 50,000 GenAI Professionals through its global training program, As part of the program, Hitachi will include training on Google Cloud’s GenAI solutions and AI technology.
GlobalLogic and Google Cloud have collaborated for more than 15 years and helped empower enterprises with solutions that achieve their business objectives with efficiency and scale.
“Through this partnership, Hitachi will leverage Google Cloud's AI capabilities to improve and enhance employee productivity and accelerate innovation. By augmenting the capabilities of our developers and customer success units with Google Cloud GenAI solutions, such as Vertex AI and Gemini models, Hitachi will be able to better serve the needs of its customers in diverse industries and across complex domains such as energy, mobility, manufacturing and digital services,” said Toshiaki Tokunaga, Executive Vice President and Executive Officer at Hitachi.
Nitesh Banga, CEO, Digital Engineering Business Unit, Hitachi, and President & CEO, GlobalLogic, added: “Through this global alliance, Hitachi is strategically aligning its go-to-market approach together with Google Cloud to drive tangible results. We are establishing clear pathways for collaboration, ensuring enhanced efficiency and acceleration in delivering solutions to our collective clients. This investment in building our Google Cloud Business Unit will provide the necessary energy, focus, and cohesive teamwork essential for achieving the desired accelerated time-to-market, translating innovation into swift revenue growth.”
“To solve complex business challenges with generative AI, enterprises need advanced technology and the technical expertise to successfully deploy it throughout their organizations,” said Thomas Kurian, CEO of Google Cloud. “Our partnership with Hitachi will provide customers with the resources needed to optimally build, implement, and manage every stage of their generative AI projects.”
About Google Cloud
Google Cloud is the new way to the cloud, providing AI, infrastructure, developer, data, security, and collaboration tools built for today and tomorrow. Google Cloud offers a powerful, fully integrated and optimized AI stack with its own planet-scale infrastructure, custom-built chips, generative AI models and development platform, as well as AI-powered applications, to help organizations transform. Customers in more than 200 countries and territories turn to Google Cloud as their trusted technology partner.
About Hitachi, Ltd.
Hitachi drives Social Innovation Business, creating a sustainable society through the use of data and technology. We solve customers' and society's challenges with Lumada solutions leveraging IT, OT (Operational Technology) and products. Hitachi operates under the 3 business sectors of “Digital Systems & Services” – supporting our customers’ digital transformation; “Green Energy & Mobility” – contributing to a decarbonized society through energy and railway systems, and “Connective Industries” – connecting products through digital technology to provide solutions in various industries. Driven by Digital, Green, and Innovation, we aim for growth through co-creation with our customers. The company’s revenues as 3 sectors for fiscal year 2023 (ended March 31, 2024) totaled 8,564.3 billion yen, with 573 consolidated subsidiaries and approximately 270,000 employees worldwide. For more information on Hitachi, please visit the company's website at https://www.hitachi.com.
About GlobalLogic
GlobalLogic (www.globallogic.com) is a leader in intelligent digital engineering. We help brands across the globe design and build innovative products, platforms, and digital experiences for the modern world. By integrating experience design, complex engineering, and data expertise—we help our clients imagine what’s possible and accelerate their transition into tomorrow’s digital businesses. Headquartered in Silicon Valley, GlobalLogic operates design studios and engineering centers around the world, extending our deep expertise to customers in the automotive, communications, financial services, healthcare and life sciences, manufacturing, media and entertainment, semiconductor, and technology industries. To learn more, visit www.globallogic.com.
About Hitachi Vantara
Hitachi Vantara is transforming the way data fuels innovation. Hitachi Vantara provides the data foundation the world's leading innovators rely on. Through data storage, infrastructure systems, cloud management and digital expertise, the company helps customers build the foundation for sustainable business growth. To learn more, visit www.hitachivantara.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240528994957/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom